New Delhi, December 11 (SocialNews.XYZ) Over the past 18-24 months, Indian pharma companies, which have benefited from sector tailwinds such as stable generic prices, raw material opportunities due to shortages and stable costs, are facing discrimination. further progress will be made in the field of standardized pharmaceuticals. Wednesday’s report showed that complex generic drugs will enter the U.S. market in 2025.
According to a report by HSBC Global Research, these tailwinds are expected to continue into 2025, as “demand and supply dynamics do not appear to have changed significantly.”
According to the memo, “Indian companies could launch gAbraxane, gAdvair inhalers, peptides, etc. in 2025, with further advances in differentiated/complex generic medicines (peptides, inhalers) in the US.” We anticipate that we will achieve this goal.”
Advances in complex generics and biosimilars will continue to be a focus as they are critical to weathering gRevlimid’s decline and sustaining growth.
With the tailwind of stable generic prices, “we believe the execution of our major new product (Abraxane for Cipla) will determine the direction of U.S. sales in 2025.”
According to HSBC, the Indian company plans to begin its efforts in GLP-1 drugs with the launch of a generic version of liraglutide (although the U.S. is far from launching generic versions of new generation GLP-1 drugs).
“We expect the Indian Pharmaceutical Market (IPM) to continue growing at a high single-digit rate due to price increases and new product launches,” it added.
In other markets (India and emerging markets), companies continue to focus on differentiated opportunities such as OTC products, biosimilars and proprietary products.
For India’s formulations business, the global research firm has assumed that the broader Indian pharmaceutical market (IPM) will grow in the high single digit range.
“Growth contributions from price increases (4% to 6%) and new product launches (2% to 3%) should remain stable going forward. We expect the contribution from volume growth to remain largely in the low single digit range. HSBC said.
Earlier this month, the Union government approved an outlay of Rs 15,000 crore for the production-linked incentive (PLI) scheme for pharmaceuticals aimed at boosting domestic manufacturing.
Source: IANS
About Gopi
Gopi Adusumlli is a programmer. He is the editor of SocialNews.XYZ and president of AGK Fire Inc.
He enjoys designing websites, developing mobile applications, and publishing news articles on current events from various trusted news sources.
When it comes to writing, I like to write about current world politics and Indian cinema. His future plans include developing SocialNews.XYZ into a news website that is free of bias and judgment.
Contact him at gopi@socialnews.xyz.
